Inclusion Criteria:

- Histologically or cytologically proven prostate cancer, locally advanced or
metastatic, or rising PSA (prostate-specific antigen)after failed local therapy, and
the patient scheduled to receive androgen deprivation therapy

- Serum testosterone levels ≥ 125 ng/dl (1.25 ng/ml, 1.25 microg/l, 4.3 nmol/l)
measured by any laboratory or on site within the previous 6 months or at study start

- Karnofsky performance index > 70

- Expected survival ≥ 9 months

Exclusion Criteria:

- Prior hormonal treatment for prostate cancer including GnRH agonists or antagonists
within the last 12 months preceding the study or concomitant treatment with one or
more of these substance(s)

- Any current use or within 6 months prior to treatment start of medications which are
known to affect the metabolism and/or secretion of androgenic hormones: ketoconazole,
aminoglutethimide, oestrogens and progesterone

- Patient at risk of spinal cord compression or ureter obstruction

- Prior hypophysectomy or adrenalectomy